Experts say Afrezza's tepid launch may have more to do with value proposition than product positioning.
Drugmakers engage early with insurers; patients push for implant to be pulled from the market; about one-third of new drugs qualify for special approval pathways
Novo Nordisk's Saxenda to cost $1,000 a month; Boehringer Ingelheim's drug receives priority review; AbbVie's hep.-C treatment Viekira Pak generates $231 million in first-quarter sales
Americans spent 13.1% more on prescription medications in 2014 than they did in 2013, but recent launches indicate competition in the specialty drug space is going to heat up.
After weeks of speculation as to whether MannKind would find a marketing partner for its inhalable insulin, the drugmaker said today that Sanofi would acquire global licensing rights to the drug for $925 million.
The painkiller's marketer will look to partner with another manufacturer to better target primary care physicians, and will also reexamine its sales territories.
Arena's recent quarter shows weight-loss drug Belviq is on the rise. It follows a DTC push and the recent addition of reps by co-marketer Eisai.
Afrezza was heralded as one of the most innovative diabetes products of the last decade. So, why hasn't MannKind set a firm launch date for the product?
Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.
Kynamro's slow start, coupled with competition, has prompted Sanofi to add sales reps.
Prescription data shows Gilead's Sovaldi is winning prescriptions at a faster rate than Vertex's Incivek did at launch.
The MS pill saw rapid uptake in the US last year, but its overseas launch won't be as quick, CEO George Scangos conceded this week at an analyst conference.
A 15% increase in sales came on the back of HIV franchise meds Stribild and Complera/Eviplera.
Based on its first three months on market, Tecfidera is one launch that's living up to its hype.
Early sales of NPS's Gattex have soared, while those of Protalix's Elelyso have been sluggish, underscoring the challenges of rare-disease launches.
While a strong launch of CF drug Kalydeco helped to hike the biotech's forecast, hep. C contender VTX-135 was hit with a partial clinical hold.
Medical science liaisons will educate nuclear-medicine clinicians as part of the launch of a new Navidea diagnostic agent for use in breast and skin cancer.
Should the FDA give the thumbs-up to J&J diabetes pill Invokana tomorrow, expect a blockbuster US marketing push, says CSD's Jerry Maynor.
Two-fifths of US neurologists polled said they're warehousing MS patients in anticipation of Tecfidera, though pricing worries could dampen sales.
Medical agency Wishbone was acquired years ago, but the leadership team behind the shop is coming out of retirement with a new venture, dubbed Calcium.
Dendreon is readying a $5 million-per-quarter "targeted" DTC advertising campaign as the company seeks to goose sluggish growth in sales of its prostate cancer treatment Provenge.
After several years of quiet among prescription sleep aids, Purdue Pharma has issued a wake up call to the category with an ad campaign featuring an adorably memorable anthropomorphic lightbulb.
The company is beefing up its marketing staff, using an iPad-equipped mix of in-house and contracted talent.
Bristol-Myers Squibb issued relatively upbeat guidance for 2013, but much depends on the performance of Eliquis.
Eliquis was approved Friday for preventing strokes in patients with nonvalvular atrial fibrillation, becoming the third oral anticoagulant to reach the US market.
OraSure, the maker of the recently-approved home HIV test, has hired an experienced consumer marketer from Pfizer to head up the launch as it readies a TV ad campaign.
Facing lower-than-expected demand, Purdue and Transcept are broadening the commercial strategy for Intermezzo to include DTC and a larger selling force.
Sanofi Pasteur has launched its first consumer advertising for Fluzone Intradermal, featuring a prickly pitch-critter meant to stress the flu vaccine's extra-thin needle.
AstraZeneca launched a new adherence program for its antiplatelet Brilinta, dubbed Complete the Course.
The family-owned pharma cautioned that early 2012 success doesn't mean the second half will be a breeze.
Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.